Last updated 11:37AM ET
November 8, 2009
Biz/Tech
Biz/Tech
Dendreon
(2009-04-23)
(KPLU) - A Seattle biotech company, Dendreon, is developing a treatment for late-stage prostate cancer. It's hoping to produce the first cancer vaccine to receive FDA approval. KPLU's Dave Meyer looks at the company with financial commentator Greg Heberlein. © Copyright 2009, KPLU

Rose WindowKPLU is a service of
Pacific Lutheran University